Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Glizen 30 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Glizen 30

Approved

STANDARD

Glizen 30

Bal Pharma Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: c37f51a76e83f005
Company: Bal Pharma Ltd.
Type: Standard

Approval Details

Approval Id: c37f51a76e83f005
Drug Approval Philippines Name: Glizen 30
Product Name: Glizen 30
Registration Number: DRP-5769-11
Brand Name: Glizen 30
Generic Name: Gliclazide
Dosage Form: Modified-Release Tablet
Dosage Strength: 30 mg
Manufacturer: Bal Pharma Ltd.
Importer: Pharmakon Biotec Inc.
Distributor: Hale Medipoint Corp
Issuance Date: 24 June 2024
Expiry Date: 13 June 2029
Pharmacologic Category: Oral Hypoglycemic Agent
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

c37f51a76e83f005

Type

Standard

Back to Philippines FDA Approvals